Dysbiosis of the Gut Microbiome in Lung Cancer

Zhuang, He; Liang, Cheng; Wang, Yao; Zhang, Yukun; Zhao, Man-Fei; Liang, Gong-Da; Zhang, Meng-Chun; Li, Yongguo; Zhao, Jingbo; Gao, Yina; Zhou, Yujie; Liu, Shulin

doi:10.3389/fcimb.2019.00112

Cited by 169 publications

(156 citation statements)

References 57 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Less well-established links between disease and gut microbiota composition include non-gastrointestinal malignancies,61 62 autism,63 64 attention deficit disorder,65 psychiatric diseases,66 neurological diseases,67 68 chronic pain69 70 and chronic fatigue syndromes 71. Environmental risk factors including smoking can alter the microbiome.…”

Section: Resultsmentioning

confidence: 99%

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Haifer

Kelly

Paramsothy

et al. 2020

Gut

View full text Add to dashboard Cite

ObjectiveFaecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications.DesignFor these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.ResultsConsensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development.ConclusionsThese FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers.

show abstract

Section: Resultsmentioning

confidence: 99%

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Haifer

Kelly

Paramsothy

et al. 2020

Gut

View full text Add to dashboard Cite

show abstract

“…are associated with lung cancer. Furthermore, the impairment of the normal function of the gut microbiome impacts on the progression of lung cancer (Zhuang et al, 2019). In another study, lower levels of Dialister, Enterobacter, Escherichia-Shigella, Fecalibacterium, and Kluyvera but higher levels of Veillonella, Bacteroides, and Fusobacterium compared to that of the controls were found .…”

Section: Lung Cancermentioning

confidence: 95%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut-lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut-lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.

show abstract

“…On the other, it is a question still under discussion whether these changes are speci c, or this alteration of the stool microbial community re ect the changes in overall health status in the presence of a metastasis and the cancer progression itself. As an example, it is known that non-colonic malignancies, for example breast cancer and lung cancer, are also accompanied by the shifts in gut microbiome [98][99][100].…”

Section: Tumour Crc Microbial Subtypesmentioning

confidence: 99%

Tumour Microbiome-Based Subtypes of Colorectal Cancer Correlate with Clinical Variables

Zwinsová¹,

Петров²,

Hrivňáková³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLong-term dysbiosis of the gut microbiome has a significant impact on the development, progression and the aggressiveness of colorectal cancer (CRC) and may explain part of the observed heterogeneity of the disease from phenotypic, prognostic and response to treatment perspectives. Although the shifts in gut microbiome in the normal-adenoma-carcinoma sequence have been described, the landscape of microbiome within CRC and its associations with clinical variables remain under-explored. ResultsWe performed 16S rRNA gene sequencing of paired tumour tissue, adjacent visually-normal mucosa and stool swabs of N=186 patients with stage 0-IV CRC to describe the tumour microbiome and its association with clinical variable and to derive tumour microbial subtypes.We identified new genera never previously associated with CRC tumour mucosa (Flavonifractor, Haemophilus, Howardella, Pseudomonas, Sutterella, Treponema 2) or CRC (Actinobacillus, Aggregatibacter, Bergeyella, Phocaeiola, Defluviitaleaceae UCG-011, Massilia, Tyzzerella 4). The bacteria residing on tumour-mucosa were dominated by genera belonging to (potential) oral pathogens. Based on tumour microbial profiles, we stratified CRC patients into three subtypes. The subtypes were significantly associated with prognostic factors such as tumor grade, primary tumour sidedness and TNM staging, with one subtype enriched in tumours with poor prognosis. Further, we inspected the associations of microbiome with clinical variables in a subtype-agnostic setting. The primary tumour-associated clinical variables predominantly correlated with tumour mucosal microbiome, while the presence of local and distant metastases was mostly associated with the stool microbiome.ConclusionsUnderstanding the interactions of the bacteria residing on tumour mucosa within different CRC tumour microbiome subtypes will help to better understand the underlying biological background of the heterogeneity of this disease. Indeed, the tumour microbiome is a possible source of additional integrative markers of CRC patients’ survival and prognosis. We found that CRC microbiome is strongly correlated with clinical variables, but these associations are dependent on the microbial environment (tumour mucosa, normal mucosa, stool). Our study thus identifies limitations of the usage of microbiome composition as marker of CRC progression, suggesting the need of combining several sampling sites (e.g. stool and tumour swabs).

show abstract

Dysbiosis of the Gut Microbiome in Lung Cancer

Cited by 169 publications

References 57 publications

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

Tumour Microbiome-Based Subtypes of Colorectal Cancer Correlate with Clinical Variables

Contact Info

Product

Resources

About